Obstructive sleep apnoea syndrome – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:24:21 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Obstructive sleep apnoea syndrome – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A study evaluating the use of semaglutide for treating obstructive sleep apnea in older adults who are overweight or have obesity https://clinicaltrials.eu/trial/study-of-semaglutide-for-the-treatment-of-obstructive-sleep-apnea-in-older-adults-who-are-overweight-or-obese/ Wed, 29 Apr 2026 15:09:44 +0000 https://clinicaltrials.eu/trial/study-of-semaglutide-for-the-treatment-of-obstructive-sleep-apnea-in-older-adults-who-are-overweight-or-obese/ This study aims to evaluate different ways to manage obstructive sleep apnea, a condition where breathing repeatedly stops and starts during sleep. The research focuses on older adults who are also living with overweight or obesity. Participants may receive semaglutide, which is administered through a subcutaneous injection, meaning the medicine is injected into the fatty layer of skin just under the surface. Some individuals might receive a placebo instead of the active medication.

During the study, researchers will monitor various health factors over a period of time. This includes tracking changes in the apnea-hypopnea index, which is a measure used to determine the severity of breathing interruptions during sleep. Other aspects being observed include daytime sleepiness, blood pressure, and changes in body weight. The study also looks at how the condition affects quality of life, sleep quality, and cognitive function, which refers to mental abilities such as memory and thinking.

]]> A study to evaluate the effects of zenagamtide in people with overweight or obesity and obstructive sleep apnoea not treated with positive airway pressure https://clinicaltrials.eu/trial/a-study-of-zenagamtide-for-people-with-overweight-or-obesity-and-obstructive-sleep-apnoea-not-treated-with-positive-airway-pressure/ Wed, 29 Apr 2026 15:09:43 +0000 https://clinicaltrials.eu/trial/a-study-of-zenagamtide-for-people-with-overweight-or-obesity-and-obstructive-sleep-apnoea-not-treated-with-positive-airway-pressure/ This study aims to investigate the effectiveness and safety of a new medication in people living with overweight or obesity and obstructive sleep apnoea. Obstructive sleep apnoea is a condition where breathing repeatedly stops and starts during sleep. This research specifically focuses on individuals who are not currently using positive airway pressure, a common treatment that uses a machine to help keep airways open during sleep.

The treatment being studied is called NNC0487-0111, which contains the active substance zenagamtide. This medication is administered via subcutaneous injection, which means it is injected into the fatty tissue just under the skin, using a pre-filled pen. Participants in the study will receive either NNC0487-0111 or a placebo once a week.

During the study, changes in body weight and the apnoea-hypopnoea index will be monitored. The apnoea-hypopnoea index is a measurement used to track how many times a person stops breathing or has shallow breathing during a sleep period. Other factors such as body mass index, which relates weight to height, and various health markers including blood pressure and cholesterol levels, may also be observed over the course of the trial.

]]> Study of zenagamtide for weight loss and sleep improvement in patients with obesity and obstructive sleep apnea using positive airway pressure therapy https://clinicaltrials.eu/trial/study-of-zenagamtide-for-weight-loss-and-sleep-improvement-in-patients-with-obesity-and-obstructive-sleep-apnea-using-positive-airway-pressure-therapy/ Wed, 29 Apr 2026 15:09:36 +0000 https://clinicaltrials.eu/trial/study-of-zenagamtide-for-weight-loss-and-sleep-improvement-in-patients-with-obesity-and-obstructive-sleep-apnea-using-positive-airway-pressure-therapy/ This study aims to evaluate the effectiveness and safety of the drug NNC0487-0111, also known as zenagamtide, in individuals living with overweight or obesity and obstructive sleep apnoea. Obstructive sleep apnoea is a condition where breathing repeatedly stops and starts during sleep. Participants in this study are already using positive airway pressure, which is a type of therapy that uses a machine to provide a steady stream of air through a mask to keep the airways open during sleep.

During the study, participants will receive either zenagamtide or a placebo via a subcutaneous injection, which means the medicine is delivered through a small needle just under the skin. The injections are administered once a week using a pre-filled pen. The study will monitor changes in body weight and the apnoea-hypopnoea index, which is a measurement used to track how many times breathing is interrupted or becomes shallow during sleep. Other aspects being observed include changes in sleep quality, blood pressure, and various blood markers.

]]> Study of Maridebart Cafraglutide for Adults with Obstructive Sleep Apnea and Overweight or Obesity Who Use Positive Airway Pressure Therapy https://clinicaltrials.eu/trial/study-of-maridebart-cafraglutide-for-adults-with-obstructive-sleep-apnea-and-overweight-or-obesity-who-use-positive-airway-pressure-therapy/ Wed, 29 Apr 2026 15:09:08 +0000 https://clinicaltrials.eu/trial/study-of-maridebart-cafraglutide-for-adults-with-obstructive-sleep-apnea-and-overweight-or-obesity-who-use-positive-airway-pressure-therapy/ This study investigates a treatment for adults living with Obstructive Sleep Apnea, a condition where breathing repeatedly stops and starts during sleep, specifically in those who also live with overweight or obesity. The participants in this study are already using Positive Airway Pressure therapy, which is a device that uses air pressure to keep the airways open during sleep. The goal of the study is to evaluate the effectiveness and safety of the drug AMG 133, also known as maridebart cafraglutide, compared to a placebo.

During the study, participants will receive either maridebart cafraglutide or a placebo through a subcutaneous injection, which means the medicine is administered just under the skin. The study will monitor changes in the Apnea-Hypopnea Index, an assessment used to measure the severity of breathing interruptions during sleep. Other factors being observed include body weight and levels of C-reactive protein, which is a substance in the blood that can indicate inflammation in the body.

]]> Study of sulthiame combined with oral appliance therapy for patients with obstructive sleep apnea who have incomplete response to oral appliance treatment alone https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-sultiame-with-oral-appliance-therapy-for-patients-with-obstructive-sleep-apnea/ Wed, 29 Apr 2026 14:59:10 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-sultiame-with-oral-appliance-therapy-for-patients-with-obstructive-sleep-apnea/ This study focuses on treating patients with Obstructive Sleep Apnea who have not achieved complete improvement with oral appliance therapy alone. The research examines the effectiveness of combining an oral appliance with sulthiame, a medication that works by inhibiting an enzyme called carbonic anhydrase in the body.

The purpose of this research is to determine if adding sulthiame to existing oral appliance therapy can help improve breathing during sleep in people whose symptoms are not fully controlled by the oral appliance alone. During the study, participants will receive either sulthiame or placebo while continuing to use their oral appliance. The medication will be given as film-coated tablets, with a daily dose of up to 200 mg.

The study will use a crossover design, meaning that participants will receive both sulthiame and placebo at different times during the research period. Each treatment period will last for two weeks. Throughout the study, participants will undergo sleep studies to measure their breathing patterns during sleep and complete questionnaires about their daytime functioning and quality of life.

]]> Study of Nacystelyn for Patients with Obstructive Sleep Apnea https://clinicaltrials.eu/trial/56674/ Wed, 29 Apr 2026 14:29:15 +0000 https://clinicaltrials.eu/trial/56674/ This clinical study focuses on examining the effects of a medication called Nacystelyn (also referred to as NAL) on patients suffering from a condition known as obstructive sleep apnea. This condition involves repeated episodes where a person’s breathing stops or becomes very shallow during sleep. The study will assess whether using Nacystelyn in the form of a dry-powder inhaler can help treat obstructive sleep apnea.

Nacystelyn will be compared to a placebo across different groups of participants. The medication is administered through an inhaler, which is a device that delivers medicine directly to the lungs when the patient breathes in. The goal of the study is to determine if Nacystelyn can effectively improve symptoms in individuals with obstructive sleep apnea over a treatment period of six weeks.

Participants in the study will receive either the Nacystelyn inhalation powder contained in hard capsules or a placebo. It aims to provide more understanding of the effectiveness and safety of this treatment in improving the sleep quality and overall health of those affected by this sleep disorder.

]]> Study on the Effect of Aprepitant on Aldosterone Levels in Patients with Obstructive Sleep Apnea and High Blood Pressure https://clinicaltrials.eu/trial/study-on-the-effect-of-aprepitant-on-aldosterone-levels-in-patients-with-obstructive-sleep-apnea-and-high-blood-pressure/ Wed, 29 Apr 2026 14:27:49 +0000 https://clinicaltrials.eu/trial/study-on-the-effect-of-aprepitant-on-aldosterone-levels-in-patients-with-obstructive-sleep-apnea-and-high-blood-pressure/ This clinical trial is focused on studying the effects of a medication called aprepitant on patients who have both obstructive sleep apnea and arterial hypertension. Obstructive sleep apnea is a condition where breathing repeatedly stops and starts during sleep, and arterial hypertension is another term for high blood pressure. The purpose of the study is to see how aprepitant affects the production of a hormone called aldosterone, which can influence blood pressure levels.

Participants in the study will be given aprepitant, which is known as a substance P antagonist. This means it works by blocking a specific receptor in the body that is involved in the production of certain hormones. The study will also use a placebo, which is a substance with no active medication, to compare the effects. Another substance involved in the study is lactose monohydrate, which is used as a tablet form. The study will be conducted over a period of time, with participants taking the medication orally, meaning by mouth.

Throughout the study, various measurements will be taken to assess the effects of the treatment. These include checking the levels of aldosterone in the body, as well as monitoring blood pressure and other related factors. The study aims to provide insights into how aprepitant can help manage conditions related to obstructive sleep apnea and high blood pressure by influencing hormone levels. Participants will be monitored closely to ensure their safety and to gather accurate data on the medication’s effects.

]]>